Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17846011 | 1.00 | CASP1 (0.42) | CASP1CYP2C19ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL4517527 | 1.00 | CASP1 (0.42) | CASP1CYP2C19ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL17846018 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CYP2D6TSHR | |
| SCHEMBL2980410 | 0.85 | ALDH1A1 (0.46) | CASP1CYP2C19ALDH1A1CYP2D6CYP3A4 | |
| SCHEMBL2980408 | 0.85 | ALDH1A1 (0.46) | CASP1CYP2C19ALDH1A1CYP2D6CYP3A4 | |
| SCHEMBL27720281 | 0.83 | MAPT (0.53) | CASP1ALDH1A1 | |
| SCHEMBL27741029 | 0.83 | MAPT (0.53) | CASP1ALDH1A1 | |
| SCHEMBL2899494 | 0.79 | CYP2C19 (0.56) | CYP2C19ALDH1A1SMN1; SMN2HTTNCOA1 | |
| SCHEMBL17846029 | 0.78 | TAS1R3 (0.44) | ALDH1A1TAS1R3TAS1R1SMN1; SMN2HTT | |
| SCHEMBL19305346 | 0.78 | MMP9 (0.49) | ALDH1A1SMN1; SMN2HTTNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ADRB2, ADRB1, ADRA2C | CASP1 3358/4885CYP2C19 540/4885ALDH1A1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.